4BIO Capital

4BIO Capital is a London-based venture capital firm focused solely on the advanced therapies sector. Their objective is to invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need. The firm aims to ensure access to these potentially curative therapies for all patients. They target viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The firm offers investors undiluted access to the fastest-growing field of medicine, and to companies, they provide the capital and expert guidance needed to succeed. 4BIO believes in a future where advanced therapies are the standard of care, and they are passionate about using the knowledge and experience of its team to help address the challenge of chronic disease. The team aims to identify companies that are likely to have a real impact on patients' lives. 4BIO's team comprises leading advanced therapy scientists and experienced life science investors. The team members have published over 250 scientific articles in prestigious academic journals, including Nature, The Lancet, Cell, and the New England Journal of Medicine. This deep scientific and investment expertise provides 4BIO with an unrivaled network within the advanced therapy sector and a unique understanding of the criteria that separate the very best investment opportunities. In-depth understanding is the key to success in the rapidly developing therapeutic landscape.